Investing

Structure Therapeutics : GPCR

GPCR

Stock Data

$42.21

$0.76 (1.83%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Structure Therapeutics Inc., based in South San Francisco, California, is a pioneering biopharmaceutical company focused on creating innovative oral treatments for chronic diseases lacking sufficient medical solutions. Its flagship product, GSBR-1290, is a groundbreaking oral medication aimed at combating type-2 diabetes and obesity by targeting a specific protein receptor involved in these conditions. Additionally, the company is working on developing new therapies for pulmonary and cardiovascular diseases, including treatments for idiopathic pulmonary fibrosis and pulmonary arterial hypertension, showcasing its commitment to addressing serious health challenges through oral therapeutics.

All Structure Therapeutics Articles

2 Articles

Trey Thoelcke | Apr 1, 2026 at 7:35 AM EDT

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual…

Ian Cooper | Sep 12, 2024 at 11:50 AM EDT

Five Top Obesity Stocks to Buy and Hold Long Term

Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX…